Pentycross C R
Br J Cancer. 1982 Feb;45(2):223-9. doi: 10.1038/bjc.1982.37.
The Tennagen test has been evaluated in "normal" subjects, patients with cancer (predominantly colorectal) and patients with non-malignant disease. The incidence of positive values was found to be higher in patients with clinically active cancer than in those with benign conditions or normal subjects. In our hands the test fell far short of the 90% reliability previously claimed. This may be partly due to an underestimate of the upper normal limit in earlier studies. A small series of follow-up studies after resection for colorectal cancer have so far failed to reveal any advantage to be gained by Tennagen tests over existing methods, but these studied will be continued.
已在“正常”受试者、癌症患者(主要是结直肠癌患者)和非恶性疾病患者中对Tennagen检测进行了评估。发现临床活动期癌症患者的阳性值发生率高于良性疾病患者或正常受试者。在我们的研究中,该检测远未达到先前声称的90%的可靠性。这可能部分是由于早期研究中对正常上限的低估。迄今为止,一小系列结直肠癌切除术后的随访研究未能揭示Tennagen检测相对于现有方法有任何优势,但这些研究将继续进行。